<DOC>
	<DOC>NCT00549185</DOC>
	<brief_summary>The primary objective is to determine the maximum tolerated dose of SAR3419 and to characterize the dose limiting toxicity(ies). Secondary objectives are to determine the anti-lymphoma activity, the global safety and the PK profile.</brief_summary>
	<brief_title>Multi-dose-escalation Safety and Pharmacokinetic Study of SAR3419 as Single Agent in Relapsed/Refractory B-cell Non Hodgkin's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma, B-Cell</mesh_term>
	<criteria>Histologically confirmed CD19positive nonHodgkin's Bcell lymphoma, relapsed or refractory after standard treatments, with no curative option with conventional therapy ECOG performance status 0 to 2 Burkitt's lymphoma, Lymphoblastic lymphoma, Chronic lymphocytic leukemia (Small lymphocytic lymphoma may be included) Chemotherapy or radiation therapy or other investigational agents within 4 weeks prior to entering the study Previous radioimmunotherapy within 12 weeks Known intolerance to infused protein products or maytansinoids Poor kidney, liver and bone marrow functions Any serious active disease or comorbid condition, which in the opinion of the principle investigator, will interfere with the safety or with compliance with the study Pregnant or breastfeeding women Patient with reproductive potential without effective birth control methods The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>